![Kevin Bruce](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kevin Bruce
Operationeel Directeur bij Censo Biotechnologies Ltd.
Profiel
Kevin Bruce is currently the Chief Operating Officer at Censo Biotechnologies Ltd.
Prior to this, he held the position of Chief Operating Officer at Roslin Cell Therapies Ltd.
from 2019 to 2023.
Actieve functies van Kevin Bruce
Bedrijven | Functie | Begin |
---|---|---|
Censo Biotechnologies Ltd.
![]() Censo Biotechnologies Ltd. Miscellaneous Commercial ServicesCommercial Services Censo Biotechnologies Ltd. operates as stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. It offers human bio-sample procurement, IPSC generation & genome editing, IPSC differentiation, assay development and screening services. The company is headquartered in Midlothian, the United Kingdom. | Operationeel Directeur | - |
Eerdere bekende functies van Kevin Bruce
Bedrijven | Functie | Einde |
---|---|---|
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Operationeel Directeur | 03-10-2023 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Censo Biotechnologies Ltd.
![]() Censo Biotechnologies Ltd. Miscellaneous Commercial ServicesCommercial Services Censo Biotechnologies Ltd. operates as stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. It offers human bio-sample procurement, IPSC generation & genome editing, IPSC differentiation, assay development and screening services. The company is headquartered in Midlothian, the United Kingdom. | Commercial Services |
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Health Technology |